



## **CURRENT REPORT**

Report date: 03.10.2025

Name of issuing company: Antibiotice SA

Headquarters: laşi, str. Valea Lupului nr. 1, zip code 707410

https://www.antibiotice.ro

E-mail: relatiicuinvestitorii@antibiotice.ro

Telephone/fax no.: +40232 209 000 / +40372 065 633

Unique registration code in the Trade Register Office: RO1973096

No. in the Trade Register: J1991000285223 Subscribed and paid-up capital: 67,133,804 LEI

The regulated market trading on which the securities are issued: Bucharest Stock Exchange

Number of shares: 671,338,040 Number of votes: 671,338,040

Main characteristics of the securities issued by the company: nominative shares, nominal value:

0.10 lei

Important event to be reported:

## CONVENING OF THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS

Based on the request of the shareholder **Infinity Capital Investments S.A.**, holding 13.0301% of the Antibiotice's share capital, the Management Board of Antibiotice S.A., convened on 03.10.2025, decided to supplement the agenda of the **Ordinary General Meeting of Shareholders** scheduled for **05.11.2025**, **at** 10<sup>00</sup>, at the company's headquarters located at City of Iaṣi, 1 Valea Lupului St, with the following items:

- 1. Election of the Management Board membes of Antibiotice S.A., for a 4-year term, by means of the cumulative voting method.
- 2. Approval of the inclusion in the mandate contracts concluded by the company with its administrators and directors of the following clause: 'In the event that the dismissal of an administrator or director who has concluded a mandate contract with the company occurs without just cause, the administrator or director shall be entitled to compensation in the amount of six (6) fixed gross monthly salaries."

Thus, the agenda of the General Meeting of Shareholders is as follows:

www.antibiotice.ro

- 1. Approval of the performance indicators for the non-executive administrators holding office for the 2025-2029 mandate, pursuant to the provisions of Article 30 of GEO no. 109/2011 on the corporate governance of public enterprises;
- 2. Approval of the performance indicators for the executive administrator holding office for the 2025-2029 mandate, pursuant to the provisions of art. 30 and 36 of GEO No. 109/2011 on the corporate governance of public enterprises;
- 3. Acknowledgement of the vacancy of an administrator's position.
- 4. Initiation of the selection procedure for an administrator, pursuant to the provisions of art. 24 of GD no. 639/2023 approving the methodological norms for establishing the selection criteria of the members of the management and supervisory boards of public enterprises.
- 5. Appointment of an interim administrator for a 5-month period, pursuant to the provisions of art. 29¹ paragraphs (1) and (2) of GEO no. 109/2011 on the corporate governance of public enterprises. Should the procedure for the selection and nomination of the permanent administrator be finalized before the expiry of the term for which the interim administrator was appointed, the permanent administrator shall be appointed immediately by the General Meeting of Shareholders, and the mandate of the interim administrator shall cease by operation of law.
- 6. Election of the Management Board membes of Antibiotice S.A., for a 4-year term, by means of the cumulative voting method.
- 7. Approval of the inclusion in the mandate contracts concluded by the company with its administrators and directors of the following clause: 'In the event that the dismissal of an administrator or director who has concluded a mandate contract with the company occurs without just cause, the administrator or director shall be entitled to compensation in the amount of six (6) fixed gross monthly salaries."

The shareholders registered at the reference date can exercise their right to attend and vote at general meeting directly, by mail or by a representative with special or general power of attorney, according to the article 105 para. 7, of Law 24/2017 on issuers of financial instruments and market operations. The access of shareholders is allowed based on the identity card, special or general power of attorney, special power of attorney authenticated or mandate, for the legal representatives.

The original vote by mail form together with a copy of the identity card for the individual shareholders or any document certifying the capacity of legal representative for the corporate shareholders or statement of accounts shall be sent to the company headquarters until 03.11.2025,  $10^{00}$  a.m.

In accordance with the art. 105 para. (23³) of Law no. 24/2017 on the issuers of financial instruments and market operations and by applying the provisions of para. (23¹), the "abstention" position adopted by a shareholder regarding the items on the agenda of the General Meeting of Shareholders does not represent an expressed vote.

Starting with 24.09.2025, the special or general power of attorney, the mail voting form, the draft resolutions, as well as the materials and documents which will be the subject of deliberations will be available both in Romanian and English at the company's headquarters (Investor Relations number: +40372.065.570 +40372.065.583, fax: +40372.065.633, relatiicuinvestitorii@antibiotice.ro) and on our company website (www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-ofshareholders/OGMS 05/06.11.2025).

Until 03.11.2025, 10<sup>00</sup> a.m., the special or general power of attorney shall be submitted in original form, either in English or Romanian language, accompanied by a copy of the identity card or registration certificate of the shareholder represented, at the company's headquarters or sent via e-mail, with extended electronic signature. In the event that a shareholder mandates a credit institution which provides custody services, to attend and vote in the general meetings, only the original special power of attorney is needed accompanied by an original affidavit issued by the credit institution (according to the article 207 of the FSA Regulation no. 5/2018 on issuers of financial instruments and market operations).

One or more shareholders representing, individually or together, at least 5% of the Company's share capital has/have the right:

- a) to introduce new items on the agenda of the General Meetings of Shareholders accompanied by a justification or by draft resolutions proposed for approval by the General Meetings of Shareholders;
- b) to submit draft resolutions for new items included or proposed to be added on the agenda of the General Meetings of Shareholders.

The rights specified under the letters a and b can only be exercised in writing, the formulated proposals to be sent by courier services or by electronic means. Shareholders can exercise the rights specified under the letters a and b within 15 days from the date of publication of the Convening Notice in the Official Gazette of Romania.

In cases where the exercise of the right provided for in letter a) determines the modification of the agenda of the General Meeting already communicated to the shareholders, the company will make available a revised agenda, using the same procedure as that used for the previous agenda, before the reference date of the general meeting of shareholders, so that to allow the other shareholders to appoint a representative or, if applicable, to vote by mail.

The list containing information on the name, place of residence and professional qualification of the persons proposed for the position of administrator is published on the company's website at the shareholders' disposal, and can be consulted and completed by them. The deadline for receiving proposals of candidates for the positions of administrators is 27.10.2025.

The company's shareholders can ask questions regarding the items on the agenda of the General Meetings until 05.11.2025, 10<sup>00</sup> a.m., at the e-mail address: <u>relatiicuinvestitorii@antibiotice.ro</u>.

In all the above cases, with the exception of the special or general power of attorney granted by a shareholder to a credit institution which provides custody services, the legal entity shareholders prove their legal representative status, with the legal representative's identity card together with an ascertaining certificate issued by the Trade register, or any other document issued by a competent authority in the State where the shareholder is legally registered, which certifies the capacity of legal representative. The documents will be presented in original or in copy conforming to the original. The ascertaining certificate or the equivalent document attesting the legal representative capacity of the legal entity shareholder will be issued no later than 30 days before the date of the General Meeting of Shareholders. These documents certifying the capacity of legal representative drawn up in a foreign language, other than English, will be accompanied by a translation in Romanian or in English made by an authorized translator, without being legalized or apostilled (Art. 194 of Regulation 5/2018 on issuers of financial instruments and market operations).

In accordance with art. 198 and art. 199 of Regulation 5/2018 on issuers of financial instruments and market operations, in the case of shareholders who ask questions or make proposals to complete the agenda, they can attest their identity also by submitting the account statement which proves the shareholder status as well as the number of shares held, issued by the central depository or, as the case may be, by the indirect participants who provide custody services (according to art. 146 paragraph 4<sup>1</sup> of Law no. 297/2004).

More detailed information on shareholders rights can be accessed on the company's website (www.antibiotice.ro).

At this General Meeting of Shareholders, all the shareholders registered in the Shareholders Register by the end of 24.10.2025, established as reference date are entitled to attend and vote.

If the statutory quorum is not met for the validity of the deliberations at the first call, the General Meeting shall be rescheduled for 06.11.2025, at  $10^{00}$  a.m. at the same address and with the same agenda.

President of the Management Board, Jur. Ionut-Sebastian IAVOR